Crucell NV's ongoing collaboration with Harvard Medical School to develop vaccine technology using adenovirus-based vectors received a $19.2 million boost from the National Institutes of Health. (BioWorld Today)

Crucell NV's ongoing collaboration with Harvard Medical School to develop vaccine technology using adenovirus-based vectors received a $19.2 million boost from the National Institutes of Health. (BioWorld Today)